Impairment of KCa2.3 and KCa3.1 channel activation or gene expression contributes to endothelial dysfunction, and pharmacological activation of these channels has been suggested to improve endothelial function in animal models of cardiovascular disease and diabetes9, 10. Here, KCNN3 is linked to cardiovascular disorder.